mRNA：治疗学与全球市场

预计全球 mRNA 治疗市场将保持平稳或略有下降，从 2025 年的 77.1 亿美元下降至 2030 年底的 76.9 亿美元，2025 年至 2030 年的复合年增长率为 -0.04%。

预计全球 COVID mRNA 治疗市场规模将从 2025 年的 76.5 亿美元小幅下降至 2030 年底的 75.8 亿美元，在 2025 年至 2030 年的预测期内复合年增长率为 -0.2%。

全球非 COVID 疾病 mRNA 治疗市场预计将从 2025 年的 6,170 万美元增长到 2030 年底的 1.189 亿美元，预测期内（2025-2030 年）的复合年增长率为 14%。

调查范围

本报告分析了全球mRNA疗法市场，包括2024年基准年的全球销售额（百万美元）、2025年的预估数据以及到2030年的年复合成长率(CAGR)预测。报告检验了各种类型的mRNA及其治疗应用。报告还重点介绍了mRNA专利和临床试验，并讨论了预测期内将影响市场的趋势。报告还介绍了主要企业及其策略联盟和伙伴关係关係。全球市场细分为北美、欧洲、亚太地区和世界其他地区。

报告内容

• 19 个资料表和 71 个附加表
• 全球传讯RNA（mRNA）治疗市场概况与分析
• 全球市场趋势分析，包括 2022 年至 2024 年的收益数据、2025 年的估计值以及 2030 年的复合年增长率预测
• 全球 mRNA 市场规模和收益预测估计，以及按疾病类型、适应症和地区进行的市场份额分析
• 有关市场动态、机会和阻碍因素、技术进步、法规和宏观经济变数影响的事实和数据
• 波特五力模型、全球供应链和PESTLE分析的见解
• 专利分析，包括主要授权和公布的专利
• 概述产业永续性趋势和 ESG 发展，重点在于主要企业实施的 ESG 实践、ESG评级和消费者意识
• 产业结构分析，包括企业市场占有率和排名、策略联盟、併购和创业融资前景
• 主要企业，包括 Moderna Inc.、辉瑞公司、BioNTech SE、默克公司和赛诺菲

目录

第一章执行摘要

第二章 市场概况

• 技术背景
• RNA疗法的演变
• DNA 与 RNA 疗法
• RNA疗法
• mRNA作为治疗剂
• mRNA疫苗的监管核准
• 美国关税对mRNA疗法市场的影响
• 结论

第三章市场动态

• 概述
• 市场驱动因素
• 大流行病和流行病呈上升趋势
• 意识到接种疫苗的必要性
• 投资mRNA治疗药物研究
• 市场限制
• mRNA疫苗的局限性
• 生产和物流障碍
• 市场机会
• 个人化癌症疫苗
• mRNA疗法在治疗各种疾病的潜力

第四章：监理现状

• 监管情景
• 监理机构概览
• mRNA疫苗指南和标准
• 临床前和临床评估
• 生产和上市后监测
• 持续监控与风险管理

5. 研发管线和临床试验分析

• 摘要
• mRNA疫苗

第六章市场区隔分析

• 细分市场
• 按疾病类型分類的市场
• 摘要
• COVID mRNA疫苗
• 非COVID-19 mRNA疫苗和疗法
• 按适应症分類的市场
• 癌症
• 感染疾病
• 罕见疾病
• 其他的
• 按地区细分
• 按地区分類的市场
• 摘要
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第七章 新兴科技与发展

• mRNA治疗的新兴技术
• 奈米粒子
• 修饰的mRNA
• 自动mRNA合成试剂套件
• 生物平台
• 人工智慧
• mRNA 治疗公司的 AI 开发

第八章专利分析

第九章 mRNA 治疗产业的永续性：ESG 视角

第十章 竞争讯息

• 摘要
• mRNA治疗市场主要企业（2024年）
• 战略分析
• 合作与伙伴关係
• 监管部门核准
• 临床试验数据
• 资金和津贴

第十一章 附录

• 调查方法
• 简称
• 来源
• 公司简介
• ARCTURUS THERAPEUTICS INC.
• ASTRAZENECA
• BIOCINA
• BIONTECH SE
• CUREVAC SE
• ETHRIS GMBH
• GENNOVA BIOPHARMACEUTICALS LTD.
• GSK PLC.
• IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
• MERCK & CO. INC.
• MODERNA INC.
• NUTCRACKER THERAPEUTICS INC.
• PFIZER INC.
• PROVIDENCE THERAPEUTICS
• SANOFI
• STRAND THERAPEUTICS INC.

The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.

The global market for COVID mRNA therapeutics was valued at $7.65 billion in 2025 and is forecast to slightly decline to $7.58 billion by the end of 2030, at a CAGR of -0.2% during the forecast period of 2025 to 2030.

The global market for non-COVID diseases mRNA therapeutics was valued at $61.7 million in 2025 and is forecast to reach $118.9 million by the end of 2030, at a CAGR of 14% during the forecast period of 2025 to 2030.

Report Scope

The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).

Report Includes

• 19 data tables and 71 additional tables
• An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
• Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
• Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, global supply chain and PESTLE analyses
• Patent analysis, featuring key granted and published patents
• Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
• Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• COVID mRNA Vaccines
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Technology Background
• Evolution of RNA Therapeutics
• DNA Therapeutics vs. RNA Therapeutics
• RNA Therapeutics
• mRNA as Therapeutics
• Regulatory Agency-Approved mRNA Vaccines
• Porter's Five Forces Analysis
• Potential for New Entrants
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitute Products or Services
• Industry Competition
• Impact of U.S. Tariffs on the mRNA Therapeutics Market
• Conclusion

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Rising Numbers of Pandemics and Epidemics
• Awareness of the Need for Vaccinations
• Investments in mRNA Therapeutics Research
• Market Restraints
• Limitations of mRNA Vaccines
• Production and Logistical Hurdles
• Market Opportunities
• Personalized Cancer Vaccines
• Potential of mRNA Drugs to Treat Various Diseases

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• Overview of Regulatory Bodies
• Guidelines and Standards for mRNA Vaccines
• Preclinical and Clinical Evaluation
• Manufacturing and Post-Marketing Surveillance
• Continual Monitoring and Risk Management

Chapter 5 Pipeline and Clinical Trial Analysis

• Takeaways
• mRNA Vaccines

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Disease Type
• Takeaways
• COVID mRNA Vaccines
• Non-COVID mRNA Vaccines and Therapeutics
• Market Breakdown by Indication
• Cancer
• Infectious Diseases
• Rare Diseases
• Others
• Geographic Breakdown
• Market Breakdown, by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Emerging Technologies and Developments

• Emerging Technologies in mRNA Therapeutics
• Nanoparticles
• Modified mRNA
• Automated mRNA Synthesis Kits
• Bio Platforms
• Artificial Intelligence
• AI Developments at mRNA Therapeutics Companies

Chapter 8 Patent Analysis

• Takeaways
• mRNA Publications
• List of Patents

Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective

• Sustainability in the mRNA Therapeutics Industry
• ESG Risk Ratings
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC Research

Chapter 10 Competitive Intelligence

• Takeaways
• Leading Companies in the mRNA Therapeutics Market, 2024
• Strategic Analysis
• Collaborations and Partnerships
• Regulatory Approvals
• Clinical Trials Data
• Funding and Grants

Chapter 11 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ARCTURUS THERAPEUTICS INC.
• ASTRAZENECA
• BIOCINA
• BIONTECH SE
• CUREVAC SE
• ETHRIS GMBH
• GENNOVA BIOPHARMACEUTICALS LTD.
• GSK PLC.
• IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
• MERCK & CO. INC.
• MODERNA INC.
• NUTCRACKER THERAPEUTICS INC.
• PFIZER INC.
• PROVIDENCE THERAPEUTICS
• SANOFI
• STRAND THERAPEUTICS INC.

List of Tables

• Summary Table : Global Market for mRNA Therapeutics, by Disease, Through 2030
• Table 1 : Evolution of RNA Therapeutics
• Table 2 : Approved mRNA Vaccines, 2025
• Table 3 : Pandemics of the 21st Century
• Table 4 : Status of Clinical Trials for mRNA-based Drugs, 2025
• Table 5 : Clinical Trials for mRNA Vaccines, 2025
• Table 6 : Global Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 7 : Properties of the BNT162b2 Vaccine
• Table 8 : Properties of the mRNA-1273 Vaccine
• Table 9 : Properties of the CVnCoV Vaccine
• Table 10 : Global Market for COVID mRNA Therapeutics, by Region, Through 2030
• Table 11 : Global Market for Non-COVID mRNA Vaccines and Therapeutics, by Region, Through 2030
• Table 12 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
• Table 13 : Global Market for mRNA Therapeutics, by Region, Through 2030
• Table 14 : North American Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 15 : European Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 16 : Asia-Pacific Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 17 : RoW Market for mRNA Therapeutics, by Disease Type, Through 2030
• Table 18 : Organizations with the Most Published mRNA Patents
• Table 19 : Patents for mRNA Therapeutics, 2025
• Table 20 : Patents Related to mRNA Vaccines for Infectious Diseases, 2025
• Table 21 : Patents Related to mRNA Vaccines for Cancer Treatment, 2025
• Table 22 : Patents Focused on mRNA Delivery and Modification
• Table 23 : Focus Areas in ESG Metrics
• Table 24 : ESG Rankings for Major mRNA Therapeutics Companies, 2025*
• Table 25 : ESG: Environmental Overview
• Table 26 : ESG: Social Factors Overview
• Table 27 : ESG: Governance Overview
• Table 28 : Collaborations and Partnerships in the mRNA Therapeutics Market, 2023-2025
• Table 29 : Regulatory Approvals in the mRNA Therapeutics Industry, 2023-2025
• Table 30 : Clinical Trial Data in the mRNA Therapeutics Market, 2022-2025
• Table 31 : Funding and Grants in the mRNA Therapeutics Market, 2023-2025
• Table 32 : Abbreviations Used in this Report
• Table 33 : Arcturus Therapeutics Inc.: Company Snapshot
• Table 34 : Arcturus Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 35 : Arcturus Therapeutics Inc.: Product Pipeline
• Table 36 : Arcturus Therapeutics Inc.: News/Key Developments, 2024-2025
• Table 37 : AstraZeneca: Company Snapshot
• Table 38 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 39 : AstraZeneca: Product Pipeline
• Table 40 : AstraZeneca: News/Key Developments, 2025
• Table 41 : BioCina: Company Snapshot
• Table 42 : BioCina: Product Portfolio
• Table 43 : BioCina: News/Key Developments, 2023-2025
• Table 44 : BioNTech SE: Company Snapshot
• Table 45 : BioNTech SE: Financial Performance, FY 2023 and 2024
• Table 46 : BioNTech SE: Product Pipeline
• Table 47 : BioNTech SE: News/Key Developments, 2023-2024
• Table 48 : CureVac SE: Company Snapshot
• Table 49 : CureVac SE: Financial Performance, FY 2023 and 2024
• Table 50 : CureVac SE: Product Pipeline
• Table 51 : CureVac SE: News/Key Developments, 2024-2025
• Table 52 : Ethris GmbH: Company Snapshot
• Table 53 : Ethris GmbH: Product Pipeline
• Table 54 : Ethris GmbH: News/Key Developments, 2023-2025
• Table 55 : Gennova Biopharmaceuticals Ltd.: Company Snapshot
• Table 56 : Gennova Biopharmaceuticals Ltd.: Product Portfolio
• Table 57 : Gennova Biopharmaceuticals Ltd.: News/Key Developments, 2023
• Table 58 : GSK PLC: Company Snapshot
• Table 59 : GSK PLC: Financial Performance, FY 2023 and 2024
• Table 60 : GSK PLC: Product Pipeline
• Table 61 : GSK PLC: News/Key Developments, 2024
• Table 62 : Immorna Biotechnology Co. Ltd.: Company Snapshot
• Table 63 : Immorna Biotechnology Co. Ltd.: Product Pipeline
• Table 64 : Immorna Biotechnology Co. Ltd: News/Key Developments, 2024-2025
• Table 65 : Merck & Co. Inc.: Company Snapshot
• Table 66 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 67 : Merck & Co. Inc.: Product Pipeline
• Table 68 : Merck & Co. Inc.: News/Key Developments, 2023
• Table 69 : Moderna Inc.: Company Snapshot
• Table 70 : Moderna Inc.: Financial Performance, FY 2023 and 2024
• Table 71 : Moderna Inc.: Product Pipeline
• Table 72 : Moderna Inc.: News/Key Developments, 2024-2025
• Table 73 : Nutcracker Therapeutics Inc.: Company Snapshot
• Table 74 : Nutcracker Therapeutics Inc.: Product Portfolio
• Table 75 : Nutcracker Therapeutics Inc.: News/Key Developments, 2024-2025
• Table 76 : Pfizer Inc.: Company Snapshot
• Table 77 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 78 : Pfizer Inc.: Product Portfolio
• Table 79 : Pfizer Inc.: News/Key Developments, 2024
• Table 80 : Providence Therapeutics: Company Snapshot
• Table 81 : Providence Therapeutics: Product Pipeline
• Table 82 : Providence Therapeutics: News/Key Developments, 2022-2024
• Table 83 : Sanofi: Company Snapshot
• Table 84 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 85 : Sanofi: Product Pipeline
• Table 86 : Sanofi: News/Key Developments, 2024-2025
• Table 87 : Strand Therapeutics Inc.: Company Snapshot
• Table 88 : Strand Therapeutics Inc.: Product Pipeline
• Table 89 : Strand Therapeutics Inc.: News/Key Developments, 2024-2025

List of Figures

• Summary Figure : Global Market Shares of mRNA Therapeutics, by Disease, 2024
• Figure 1 : Porter's Five Forces Analysis
• Figure 2 : Snapshot of Market Dynamics
• Figure 3 : Factors Responsible for the Rising Number of Pandemics
• Figure 4 : Clinical Trials for mRNA Vaccines, by Disease Indication, 2023-2025
• Figure 5 : mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023-2025
• Figure 6 : mRNA Vaccine Candidates in Clinical Trials, by Study Type, 2023-2025
• Figure 7 : mRNA Vaccine Candidates in Clinical Trials, by Funding Source, 2023-2025
• Figure 8 : Global Market Shares of mRNA Therapeutics, by Disease Type, 2024
• Figure 9 : Global Cancer-Related Deaths, by Cancer Type, 2000-2030
• Figure 10 : Global Market Shares of mRNA Therapeutics, by Region, 2024
• Figure 11 : Emerging Technologies in mRNA Therapeutics
• Figure 12 : Patents on mRNA Therapeutics, 2010-2022
• Figure 13 : Patent Shares on mRNA Therapeutics, by Patent Classification, 2010-2021
• Figure 14 : Published mRNA-based Patents, 2019-2022
• Figure 15 : How a Strong ESG Proposition Can Benefit Businesses
• Figure 16 : Moderna's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
• Figure 17 : BioNTech's mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
• Figure 18 : Arcturus Therapeutics Inc: Revenue Shares, by Business Unit, FY 2024
• Figure 19 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 20 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 21 : BioNTech SE: Revenue Shares, by Region/Country, FY 2024
• Figure 22 : GSK PLC: Revenue Shares, by Business Unit, FY 2024
• Figure 23 : GSK PLC: Revenue Shares, by Region/Country, FY 2024
• Figure 24 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 25 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 26 : Moderna Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 27 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 28 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 29 : Sanofi: Revenue Shares, by Country/Region, FY 2024